Fas death receptor signalling: roles of Bid and XIAP

T Kaufmann; A Strasser; PJ Jost

Journal article

Fas death receptor signalling: roles of Bid and XIAP

T Kaufmann, A Strasser, PJ Jost

CELL DEATH AND DIFFERENTIATION | NATURE PUBLISHING GROUP | Published : 2012

DOI: 10.1038/cdd.2011.121

Abstract

Fas (also called CD95 or APO-1), a member of a subgroup of the tumour necrosis factor receptor superfamily that contain an intracellular death domain, can initiate apoptosis signalling and has a critical role in the regulation of the immune system. Fas-induced apoptosis requires recruitment and activation of the initiator caspase, caspase-8 (in humans also caspase-10), within the death-inducing signalling complex. In so-called type 1 cells, proteolytic activation of effector caspases (-3 and -7) by caspase-8 suffices for efficient apoptosis induction. In so-called type 2 cells, however, killing requires amplification of the caspase cascade. This can be achieved through caspase-8-mediated pro..

View full abstract

University of Melbourne Researchers

Andreas Strasser Author Medical Biology (w.e.h.i.)

Related Projects (1)

CELL DEATH PATHWAYS AND TYPE 1 DIABETES

Loss of insulin-producing beta cells leads to type 1 diabetes and rejection of allogeneic islet transplants. The aim of this program is to d..

Grants

Awarded by Australian NHMRC

Awarded by NIH

Awarded by Leukemia and Lymphoma Society (LLS)

Awarded by JDRF/NHMRC

Awarded by Swiss National Science Foundation

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

We dedicate this review to the memory of Juerg Tschopp, wonderfully generous human being and outstanding scientist, who left behind not only important scientific discoveries, but also, importantly, the novel treatments for several inflammatory diseases. He will be solely missed. We thank all the present and the past members of the apoptosis research programs at WEHI, particularly Drs JM Adams, S Cory, D Vaux, J Silke, D Huang, P Colman, P Bouillet, R Kluck and C Scott, for their outstanding contributions and stimulating discussions. Research in our laboratories is supported by fellowships and grants from the Australian NHMRC (257502, 461299), NIH (CA 043540), Leukemia and Lymphoma Society (LLS SCOR 7413), JDRF/NHMRC (466658), the Max-Eder Program grant from the Mildred Scheel-Stiftung/Deutsche Krebshilfe, the Novartis Foundation for Medicine and Biology, and the Swiss National Science Foundation (PP00A-119203).